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Summary: The commonly used immunosupprcssivc regimen after solid organ transplantation consists of eyclo-
sporine A, azathioprinc and steroids. Azathioprine, which is known to carry the risk of severe myelosuppression,
is catabolized in vivo by xanthine oxidase and thiopurinc methyltransferase, an enzyme which exhibils a common
genetic polymorphism; 11% of Caucasians are heterozygous and 0.3% are homozygous wilh respect to thiopurinc
methyltransferase deficiency. Toxicity and immunosuppressive effects have been attributed to the 6-thioguaninc
nucleotides generated from azathioprinc. We have studied thiopurine methyltransferase activity and 6-thioguaninc
nucleoiide concentrations in erylhrocytcs from 39 heart and kidney recipients. Brythrocylc thiopurine methyl-
transferase was determined by a radioen/ymatic assay and erylhrocyte 6-thiogimninu niicleotidc concentration with
I1PLC. Thiopurinc methyltransferase activity [median (range, l()lll~90th percentile)] was significantly (p < 0,05)
higher in patients (n - 39) receiving axathioprine [285 (218-362) vs, 262 (160-352) inU/l erythrocylcs] than in
healthy blood donors as controls (n = 120). When stratified according to thiopurinc methyltransferase phenotypc,
one patient homozygous for the low allele exhibited an excessive crylhrocyte 6-lhioguaninc nuclcotide concentration
(2210 pmol/0.8 · I09 erylhrocytcs). Heterozygous patients had significantly higher 6-thioguaninc niicleotidc concen-
trations (median: 435 pmol/0.8 · 1 erythrocytes) compared with concentrations in patients homoxygous for the
high allele (median: 86 pmol/0.8 · 10(J erythrocytes; < 0.01), although the azalhioprine dosage did not differ
(p = 0.66). Erythrocytc thiopurine methyltransferase determination therefore identifies patients at high risk of accu-
mulating 6-thioguanine nucleotides. The monitoring of this enzyme may contribute to the safer management of
immunosuppressive therapy with axathioprine. Alternative regimens such as cyclosporin A/mycophenolate mofet i I
or tacrolimus should also be considered for this patient group.
Introduction
In immunosuppressive cyclosporin-based triple therapy transferase. Xanthine oxidase is not genetically poly-
aficr organ transplantation, axathioprine is often used us morphic and if not pharmacologically blocked this path-
an antiproliforative agent. Azathioprine represents the S- way leads to 6-thiourie acid. In contrast, thiopurinc
imidaxolc derivative of 6-mercaptopurine and is rapidly melhyltransferase displays a common genetic polymor-
cleaved to this drug in vivo by glutathione-S-transfcrasc phism ( 1 1 — 13). This polymorphism leads in 0.3% of
(1). It is generally agreed that 6-thioguaninc nueleotidos, Caucasians to a complete deficiency of the enzyme, and
which are synthcsiscd from 6-mercaptopurine through in about 11% to a heterozygous form with an enzyme
several enxymatic steps including hypoxanthine-gua- activity of 40—60%, compared with individuals with the
nine-phosphoribosyl transferase (2), are the major toxic two high allelcs (14). An accumulation of 6-thioguaninc
species of 6-thiopurine derivatives (fig. 1) (3, 4). The nucleotides is therefore likely to occur if one of these
determination of 6-thioguanine nucleotides in crythro- eatabolising pathways is altered. Thiopurine methyl-
cytes is therefore an accepted means of estimating toxic- transferase is generally determined in erythrocytes,
ity and efficacy of 6-mercaptopurinc treatment in pa- which are readily accessible, and there is a close correla-
tients with acute leukaemia (5—7) and after solid organ tion between activities measured in erylhrocytes and in
transplantation (8-10). 6-Thiopurines are catabolised by other cells and organs e. g. liver, kidney and leukocytes
two enzymes, xanthine oxidase and thiopurine methyl- (15-17). Brythrocyte thiopurine methyltransferase of
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phosphoribosyl transferase; IMPDH:Inosine monophosphate dehy-
randomly selected healthy Europeans typically shows a
biphasic frequency distribution, consistent with a co-
dominant inheritance (12, 13). One single point muta-
tion, which leads to a substantial reduction of catalytic
activity has been described (18) and recently a predomi-
nant 2-point mutation, which is present in about 70%
of thiopurine methyltransferase deficient subjects was
discovered (19). Further factors complicating therapeutic
management of thiopurines are their widely variable bio-
availability (20, 21) and an increase of thiopurine
methyltransferase activity during therapy consistent with
an induction phenomenon (10, 22). These might be the
main reasons for the fact, that until now, only one study
has shown a close negative correlation between thiopur-
ine methyltransferase and 6-thioguanine nucleotides
(23).
In patients receiving thiopurines for malignancies, i. e.
where leukocyte suppression is desired, the dosage is
mainly adjusted to achieve low white blood cell count.
In contrast, in immunosuppressive triple therapy,
azathioprine is most commonly used in a protocol-based
standard dosage and only reduced if leukopenia occurs.
On the other hand, transplant recipients, compared with
acute lymphatic leukaemia and acute myeloic leukaemia
patients under maintenance therapy, are at higher risk
for complications of leukopenia since they receive a
combination of immunosuppressive drugs. They may
therefore particularly profit from therapeutic drug moni-
toring of the toxic 6-thioguanine nucleotides. Further-
more, in these patients it would be of benefit to investi-
gate the correlation of 6-thioguanine nucleotides and
drogenase; XO: Xanthine oxidase; TPMT: Thiopurine methyl
transferase; SAH: S-Adenosyl homocysteine; SAM: S-Adenosyl
methionine
thiopurine methyltransferase in vivo, since if thiopurine
methyltransferase phenotype is correlated with toxic me-
tabolites, a stratification of each patient according to
thiopurine methyltransferase activity prior to therapy
may aid in planning subsequent immunosuppressive
therapy, particularly with respect to the new immuno-
suppressants.
We studied erythrocyte thiopurine methyltransferase ac-
tivity and 6-thioguanine nucleotide concentrations in 39
patients after heart and kidney transplantation under sta-
ble clinical conditions at least 3 months after the last
blood transfusion, to elucidate the relationship between
erythrocyte 6-thioguanine nucleotides and thiopurine
methyltransferase activity.
Patients and Methods
Probands
Twenty-one heart transplant recipients and 18 kidney recipients
with generally uncomplicated postoperative courses were included
in this study. Thirty-eight patients had undergone transplantation
at least 3 months prior to the investigation and none had blood
transfusions within this time. The only exception was one thiopur-
ine methyltransferase-deficient patient who was tested 2 months
after transplantation. The immunosuppressive regimen consisted of
cyclosporin A, the dosage being adjusted according to its concen-
trations in blood (200-350 g/l in heart recipients, 150-200 g/l
in kidney recipients), steroids, which were tapered during the post-
operative period, and azathioprine at a daily dosage median of
1 mg/kg body weight. Some patients received antilymphocyte anti-
bodies as therapy induction for a maximum of 7 days immediately
after transplantation. Patients with comedication with drugs which
can potentially influence thiopurine metabolism, particularly xan-
thine oxidase inhibitors, and patients with» unstable kidney function
(e. g. due to rejection episodes) were excluded. If patients were
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tested several times, the latest time point was considered for statis-
tical evaluation unless creatinine concentrations were increased
compared with earlier measurements in the same patient.
For comparison, blood samples of 120 healthy blood donors were
also analysed for their erythrocyte thiopurine methyltransferase ac-
tivity.
Methods
Erythrocyte preparation
Erythrocytes were obtained from NH4-heparinate anticoagulated
whole blood by centrifugation at 2000 g for 10 min. Two washing
steps were performed with Hank's balanced salt solution under the
same conditions. Cells were finally rediluted to a haematocrit of
about 0.40 and the exact haematocrit and red blood cell count for
calculations of thiopurine methyltransferase activity and 6-thiogua-
nine nucleotide concentration were determined with a Coulter
STKS cell counting device. Samples were stored at -90 °C until
analysis of thiopurine methyltransferase or 6-thioguanine nucleo-
tides.
Tliiopurine methyltransferase assay
Erythrocyte lysates were analysed for their thiopurine methyl-
transferase activity by a modified method according to Weinshil-
boum et al. (24). As proposed elsewhere, S-[me/Ay/-3H]adenosyl-
methionine was used as methyl donor (12) and the chelating step
was omitted since erythrocytes lack interfering enzymes requiring
bivalent cations (15). Lysates were incubated for l h at 37 °C with
6-mercaptopurine, S-[we///y/-3H]adenosyl-methionine, dithiothrei-
tol, and allopurinol. The formed [mef/iy/-3H]6-mercaptopurine was
liquid/liquid extracted with 120 mmol/1 isoamyl alcohol in toluene
and the radioactivity was determined by -scintillation in a model
LS3801 counter (Beckman Instruments, Munich, Germany). The
radioactivity of the total reaction mixture was also determined. Re-
sults were corrected for"quench, chemical and radiochemical purity
of S-adenosylmethionine and extraction efficacy (56-65%; deter-
mined in each run), and expressed as mU/1 packed erythrocytes).
These modifications yielded an improvement of between day varia-
tion of the erythrocyte thiopurine methyltransferase assay from
9.5% to 5.9%. Within-series imprecision was 4.1-9.0% (100-350
mU/1 erythrocytes) in our laboratory with a dynamic range of this
procedure of 17-920 mU/1 erythrocytes.
6-Thioguanine nucleotide assay
Erythrocyte lysates were hydrolysed in 1.5 mol/1 H2SO4 at 98 °C
for 1 hour, in order to convert the respective nucleotides to 6-
thioguanine. A saturated solution of phenyl mercuric acetate in tol-
uene/isoamyl alcohol at alkaline pH was used to extract com-
pounds with sulfhydryl groups. After back-extraction into 100
mmol/1 HC1, samples were analysed by C18 reversed phase HPLC
(Hypersil ODS 5 μπι 250 · 4.6 mm, MZ Analysentechnik, Mainz,
Germany, guard column: RP select B 5 μπι, Merck, Darmstadt,
Germany) under isocratic conditions (25). 6-Thioguanine spiked
drug-free erythrocyte lysates were used for construction of a cali-
bration curve with UV detection at 342 nm. 4-Mercapto-lH pyra-
zolo [3,4-d] pyrimidine was used as internal standard, and was
detected at 322 nm (Shimadzu SPD 10 AV, Shimadzu Europe, Gro-
burgwedel, Germany). If deviation from the assigned haematocrit
(0.35) of sample preparation was > 0.05, a correction was per-
formed with donor blood or Hank's balanced salt solution prior
to the hydrolysis step. This is necessary since extraction efficacy
decreases with the number of erythrocytes, with a resulting opti-
mum at an haematocrit of about 0.35. Thioguanine concentrations
were expressed as pmol/0.8 · 109 erythrocytes. Between-days im-
precision was < 7% at concentrations of 100 pmol/0.8 · 109 eryth-
rocytes and above, with a detection limit of 20 pmol/0.8 · 109 eryth-
rocytes.
All reagents were of highest available purity. S-[we//?y/-3H]adeno-
syl-methionine was purchased from Amersham (Braunschweig,
Germany), isoamyl alcohol from J. T. Baker (Devender, The Neth-
erlands) and toluene, borate, H2SO4, HC1 and NaOH from Merck
(Darmstadt, Germany). All other chemicals were from Sigma
Chem. (Deisenhofen, Germany).
Statistical analyses were performed with SAS statistical package,
Ver.6.01 (SAS Inst. New York, USA).
This study was approved by the local Ethics Committee.
Results
Erythrocyte thiopurine methyltransferase activity of 120
healthy donors showed a typical biphasic distribution
(fig. 2) with a cut-off for the putative heterozygous
group at 167 mU/1 erythrocytes. The calculated cut-off
100 150 200 250 300 350 400
Thiopurine methyltransferase [mU/1 erythrocytes]
450
Fig. 2 Frequency distribution of erythrocyte thiopurine methyl- Typical biphasic distribution with calculated lower limit for the
transferase in 120 healthy blood donors without thiopurine admin- intemiediate group of 162 mU/1 erythrocytes
istration. Groups are defined by their upper limit.
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Fig. 3 Frequency distribution of erythrocyte thiopurine methyltransferase in 39 kidney and heart
•recipients under chronic azathioprine administration. Groups are defined by their upper limit.
point, based on the llth percentile of this donor group
was 162 mU/l erythrocytes. The median for the whole
group of healthy donors was significantly lower than
in the group of patients under long-term therapy with
azathioprine (262 vs. 285 mU/l erythrocytes; p < 0.05).
In the patient group, one subject showed a total thiopur-
ine methyltransferase deficiency and five patients were
identified with an intermediate phenotype (fig. 3). The
upper limit of this intermediate group was 217 mU/l
erythrocytes, defined as the 11th percentile of the patient
group with the exclusion of the thiopurine methyl-
transferase deficient patient (since taking this case under
consideration would over-represent this group, which
has a frequency of 0.3% in a normal population).
Erythrocyte 6-thioguanine nucleotide concentrations
displayed a broad distribution from 31 to 599 pmol/0.8
• 109 erythrocytes in patients with detectable erythrocyte
thiopurine methyltransferase activity (fig. 4). The high-
est 6-thioguanine nucleotide concentration observed was
2210 pmol/0.8 · 109 erythrocytes in the thiopurine
methyltransferase-deficient patient. This was associated
with an episode of leukppenia.
0 50 100 150 200 250 300ü 400 500 600 1000 2000 >2000
6-Thioguanine nucleotides [pmol/0.8 · 109 erythrocytes]
Fig. 4 Frequency distribution of erythrocyte 6-thioguanine nucleotides in 39 kidney and heart»recipients
under chronic azathioprine administration. Groups are defined by their upper limit.
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Fig. 5 Scatterplot of 6-thioguanine nucleotides vs. thiopurine prine. One patient with thiopurine methyltransferase deficiency is
methyltransferase in erythrocytes in patients receiving azathio- not displayed (n = 38; r = -0.785).
Tab. 1 Erythrocyte 6-thioguanine nucleotide concentrations in
heart and kidney recipients stratified according to erythrocyte thio-
purine methyltransferase activity.
Thiopurine methyltransferase
(mil/I erythrocytes)
<17 17-210 >210
(n =1) (n = 5) (n = 33)
Thioguanine nucleotide concentration
(pmol/0.8 · 109 erythrocytes)
Median
84th percentile
16thpercentile
2210
_
—
436*
593
321
99
228
46
* p < 0.05 vs high thiopurine methyltransferase group
When stratified according to thiopurine methyltransfer-
ase activity, significantly higher erythrocyte 6-thiogua-
nine nucleotide concentrations were observed in the
groups with low thiopurine methyltransferase activity
(tab. 1).
Azathioprine dosage did not differ between these groups
(median 75 mg/day; p = 0.88). Furthermore there was
no correlation between azathioprine daily dose and
erythrocyte-6-thioguanine nucleotide concentrations
(r < 0.01; p = 0.431). A highly significant negative cor-
relation was seen between thiopurine methyltransferase
activity in erythrocytes and the respective concentrations
of 6-thioguanine nucleotides (fig. 5), even when the pa-
tient with total thiopurine methyltransferase deficiency
was excluded (r = -0.785; p < 0.01).
Discussion
The detoxification of azathioprine, used in immunosup-
pressive management after organ transplantation, is de-
pendent on the common genetic polymorphism of thio-
purine methyltransferase (11 — 13, 14, 27). This study
showed that thiopurine methyltransferase activity is ob-
viously influenced by thiopurines and shows an increase
under therapy. This is in close agreement with results
from studies in which thiopurine methyltransferase was
measured in patients prior to and under treatment with
azathioprine or 6-mercaptopurine, and thereafter (5, 22).
Despite the well known metabolism of thiopurines, only
one study has shown a close relationship between thio-
purine methyltransferase activity and 6-thioguanine nu-
cleotide concentrations (23). This might be due to sev-
eral uncertainties of azathioprine therapy, such as the
induction phenomenon mentioned above, different dos-
ages, especially if dosage is adjusted according to leuko-
cyte count, and the variable bioavailability of this drug
(20, 21) which is influenced by food intake (26). In this
study, we observed a close negative correlation of 6-
thioguanine nucleotides and thiopurine methyltransfer-
ase in patients taking azathioprine. In these heart and
kidney recipients, the observed highly significant corre-
lation (r = —0.785) was probably due to the relatively
constant dosage of 75 mg/day in this patient group.
High concentrations of erythrocyte 6-thioguanine nucle-
otides are associated with the risk of myelosuppression
(5-7, 10), with related complications, such as septicae-
mia and consecutive multiple organ failure. As reported
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(27), the patient with complete thiopurine methyl-
transferase deficiency and excessive 6-thioguanine nu-
cleotide concentration subsequently died from this com-
plication. Furthermore in a previous study, we showed
that patients with 6-thioguanine nucleotide concentra-
tions > 600 pmol/0.8 · 109 erythrocytes may develop
leukopenia (10). These findings suggest that one might
expect an increased risk of toxic side effects in such
patients under treatment with higher azathioprine dos-
age.
In therapeutic drug monitoring for azathioprine after
solid organ transplantation the lower limit of erythrocyte
6-thioguanine nucleotides is hard to define, since the
immunosuppressive regimen consists of a combination
of drugs and there is a lack of simple quantities for as-
sessing the immunosuppressive state of an individual
patient. The data of this study demonstrate a close rela-
tionship between thiopurine methyltransferase activity
and 6-thioguanine nucleotide concentration in transplant
recipients under azathioprine therapy. It would therefore
seem advisable to measure erythrocyte thiopurine
methyltransferase prior to transplantation, to identify
those patients with low or absent activity, who obviously
carry an increased risk for toxic complications due to
elevated 6-thioguanine nucleotides. In patients with
lower or absent thiopurine methyltransferase, the con-
centrations of 6-thioguanine nucleotides should be mon-
itored during azathioprine therapy to avoid toxic effects,
and dosage could be adjusted at the start of therapy by
taking erythrocyte thiopurine methyltransferase activity
into account. Alternatively, determination of erythrocyte
thiopurine methyltransferase prior to transplantation
could be used to identify patients at high risk of azathio-
prine toxicity, who might more appropriately be treated
with one of the new immunosuppressants such as tacrol-
imus or mycophenolate mofetil.
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